Location History:
- Castro Valley, CA (US) (2010)
- San Francisco, CA (US) (2012 - 2013)
- Moraga, CA (US) (2011 - 2023)
- Richmond, CA (US) (2024)
Company Filing History:
Years Active: 2010-2024
Title: Haishan Lin: Innovator in Monoclonal Antibodies and Cancer Treatment
Introduction
Haishan Lin is a prominent inventor based in Moraga, CA (US), known for his significant contributions to the field of monoclonal antibodies and cancer treatment. With a total of 8 patents, Lin has made remarkable strides in developing innovative therapies aimed at combating various forms of cancer.
Latest Patents
Among his latest patents, Lin has developed CLDN 18.2-specific monoclonal antibodies and methods of use thereof. These patents provide novel anti-CLDN 18.2 antibodies and chimeric antigen receptors (CAR), along with cells or compositions that comprise them. The patents also include vectors or plasmids encoding anti-CLDN 18.2 CAR, anti-CLDN 18.2 antibody-drug conjugates (ADCs), and bispecific antibodies containing anti-CLDN 18.2 antibodies. These innovations are particularly aimed at detecting or treating ovarian cancer or prostate cancer. Additionally, Lin has patented blocking antibodies against CD47 and methods of use thereof. These antibodies can effectively block the interaction between human CD47 and its ligand SIRP alpha, enhancing the phagocytosis activity of macrophages to engulf cancer cells. Some of these antibodies do not induce in vitro hemagglutination, making them suitable therapeutic agents with reduced off-target effects.
Career Highlights
Lin has worked with notable companies in the biotechnology sector, including Five Prime Therapeutics, Inc. and Accurus Biosciences, Inc. His work in these organizations has contributed to the advancement of cancer therapies and the development of innovative medical solutions.
Collaborations
Throughout his career, Lin has collaborated with esteemed colleagues such as Lewis T Williams and Li Long. These partnerships have fostered a collaborative environment that has led to significant advancements in the field of cancer research.
Conclusion
Haishan Lin's innovative work in monoclonal antibodies and cancer treatment showcases his dedication to improving therapeutic options for patients. His contributions continue to influence the landscape of cancer research and treatment methodologies.